Press releases

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th Annual Canaccord Genuity Growth Conference on August 11 in Boston and the 2016 Wedbush PacGrow Healthcare...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to...

Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer of radiofrequency ablation (RFA) systems. The...

Boston Scientific Corporation (NYSE: BSX) announced today the election of Yoshiaki Fujimori to its board of directors, effective immediately. Yoshiaki Fujimori is an adviser to the LIXIL Group...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 at

Boston Scientific Corporation (NYSE: BSX) today announced that its GreenLight XPS™ Laser Therapy System, used for the treatment of prostatic enlargement, known as benign prostatic hyperplasia...

Boston Scientific Corporation (NYSE: BSX) today announced a global restructuring program to build on the progress the company has made in executing long-term growth strategies and bringing...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs Global Healthcare Conference on June 9 in Rancho Palos Verdes. Dan Brennan, executive vice president and...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2016 Healthcare Conference on June 7, in New York City. Susie Lisa, vice president, Investor Relations, will...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Precision Montage™ MRI Spinal Cord Stimulator (SCS) System after receiving approval from the U.S. Food and Drug...

Boston Scientific (NYSE: BSX) today announced the schedule of key data that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris. Data from the 1,000-patient EWOLUTION...

Boston Scientific (NYSE: BSX) today announced results from the largest post-market registry for the Subcutaneous Implantable Defibrillator (S-ICD) System. Data collected from the EFFORTLESS study...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with the Rhythmia™ Mapping System. The IntellaNav™ XP and the...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2016 Health Care Conference on May 12, in Las Vegas. Dan Brennan, executive vice...

Boston Scientific (NYSE: BSX) today announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS)...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.964 billion during the first quarter ended March 31, 2016, compared to the company's guidance range for the quarter of $1.890 to...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for use in a magnetic resonance imaging (MRI) environment. The...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 41st Annual Health Care Conference on May 5, in Boston. Dan Brennan, executive vice president and chief...

Boston Scientific (NYSE: BSX) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling...

Boston Scientific (NYSE: BSX) has initiated a global, voluntary recall of all models of its Fetch™ 2 Aspiration Catheter, a thrombectomy catheter used during procedures to remove small blood...

Boston Scientific does not use “counterfeit” or “adulterated” materials in our medical devices. The company rejects the allegations in the petition to the Food and Drug Administration...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2016 on Wednesday, April 27,...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 15th Annual Needham Healthcare Conference on April 12, in New York City. Susie Lisa, vice president, Investor...

Boston Scientific (NYSE: BSX) today announced key data presentations spanning its interventional cardiology, rhythm management and structural heart portfolios, that will be featured at the...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the AXIOS™ Stent and Electrocautery Enhanced Delivery System to help physicians manage two serious complications from...

Boston Scientific Corporation (NYSE: BSX) and Mayo Clinic today announced a continuing collaboration where the two organizations share intellectual property and stimulate the rapid development of...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Blazer™ Open-Irrigated (OI) radiofrequency ablation catheter. The Blazer OI catheter has been...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays Global Health Care Conference on March 15, in Miami Beach. Dan Brennan, executive vice president and chief...

Boston Scientific Corporation (NYSE: BSX) announced today a number of changes to the leadership and membership of its Board of Directors. Pete M. Nicholas, the company's co-founder and chairman of...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen & Co. 36th Annual Health Care Conference on March 8, in Boston. Dan Brennan, executive vice president and chief...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the ACUITY™ X4 Quadripolar Left Ventricular (LV) leads. The FDA approval of the quadripolar leads,...

Boston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing commercialization immediately in the European Union and...

Boston Scientific Corporation (NYSE: BSX) announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial appendage closure (LAAC) therapy under specific...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.978 billion during the fourth quarter ended December 31, 2015. This represents 10 percent operational revenue growth (constant...

MARLBOROUGH, Mass. (February 1, 2016) – Boston Scientific Corporation (NYSE: BSX) today announced that Bronchial Thermoplasty (BT) delivered by the Alair™ System is now available to Tufts...

Boston Scientific Corporation (NYSE: BSX) and Accenture (NYSE: ACN) have developed a cloud-based, data-driven digital health solution for hospitals that is designed to help improve patient...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink Partners 5th Annual Global Healthcare Conference on February 10, in New York City. Dan Brennan, executive vice...

Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the LithoVue™ Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year ended December 31, 2015 on...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 in San Francisco. Mike Mahoney, president...

Final results evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provides more than 70 percent greater...

Boston Scientific (NYSE: BSX) has voluntarily recalled the Chariot™ Guiding Sheath globally. These devices are intended for the introduction of interventional devices during peripheral vascular...

Boston Scientific (NYSE: BSX) has received United States (U.S.) Food and Drug Administration (FDA) approval and CE Mark for the AngioJet™ ZelanteDVT™ thrombectomy catheter to treat deep vein...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Oppenheimer 26th Annual Healthcare Conference on December 8, in New York City. Susie Lisa, vice president, Investor...

Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...

Boston Scientific (NYSE: BSX) has received a score of 100 percent on the 2016 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices related...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray 27th Annual Healthcare Conference on December 1, in New York City. Jeff Mirviss, senior vice president...

Boston Scientific (NYSE: BSX) has entered into a definitive agreement to acquire the interventional radiology portfolio of CeloNova Biosciences, a San Antonio-based developer of endovascular and...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity 9th Annual Medical Technology and Diagnostics Forum on November 19, in New York City. David Pierce,...